Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

TSXV:XRTX - Post Discussion

XORTX Therapeutics Inc > FACTS OVER OPINIONS
View:
Post by Anklebiter42 on Nov 25, 2021 10:34pm

FACTS OVER OPINIONS

1. Stock is extremely under-valued
2. NASDAQ listing provides access to Large Institutional Investors which will drive up the share price.
3. Strong Cash. No further financing. Future cash will come through licensing agreement / partnership.
4. Spacelab is a loser!

Let the video remind you why you invested in XORTX. 

https://youtu.be/X0YEFUo3TdE
Comment by ecanadian2 on Nov 25, 2021 11:54pm
Just to be clear these are all opinons or at most educated(?) guesses: under-valued? drive-up share price? no further financing? My opinions are that: the only thing that will drive up and support the share price are tangible positive developments (on the bio research/trials front) and that funding will be required in not too distant future - 12 months? Are they much better off that they were 6 ...more  
Comment by Alex1726 on Nov 26, 2021 7:39pm
F...uck in idiot 1. Stock is extremely under-valued Based on what 2. NASDAQ listing provides access to Large Institutional Investors which will drive up the share price. So far it is not the case 3. Strong Cash. No further financing. Future cash will come through licensing agreement / partnership. Oh yes , another stupid statement 4. Spacelab is a loser! You're probably too
Comment by SpaceLabs on Nov 26, 2021 11:16pm
Spacelab is NOT a LOSER, you are you azzholes and SMART AZZES who have NO Brains , I am a GRASSROOTS you filthy PIGS with aliases on BB. Plain and SIMPLE: 1.I have never seen any junior listing  from CSE on NASDAQ where IPO is DONE by an IDIOT Dr. Allen using a NO NAME BRANDED Fund Managers discounted by 30% and ONLY 13 Million shares after Rollback. 2. PIGS on BB are all BOILER Room mates ...more  
Comment by yrunvs on Nov 27, 2021 2:49pm
Hey Space Cadet, Tell us what you really think about Dr.Allen, I am not sure if you have been clear enough the other 50 times. You are a broken record with a skip in it. SELL YOUR STOCK AND MOVE ON PLEASE, and take your other alias posters with you.
Comment by SpaceLabs on Nov 27, 2021 11:31pm
RedeNeck Answer is below: 1. 1.I have never seen any junior listing  from CSE on NASDAQ where IPO is DONE by an IDIOT Dr. Allen using a NO NAME BRANDED Fund Managers discounted by 30% and ONLY 13 Million shares after Rollback. I hope the BOILER ROOMIES understand this  and stop BS about SHAKING IT. nothing left by Allen to SHAKE, he SHOOK it and CHOPPED the BRANCHES off, tell AB42 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities